NCT04437693View on ClinicalTrials.gov

Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

December 31, 2021

Conditions
COVID 19
Interventions
DRUG

Hydroxychloroquine

The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY

NCT04437693 - Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients | Biotech Hunter | Biotech Hunter